Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Some mechanistic and class-related statements align with the FDA label, but many claims made by the AI response are outside the provided FDA label (e.g., indications beyond onychomycosis, availability/forms, patent/market statements, and several adverse-effect/general safety and interaction assertions). Several mechanistic details are partially supported but over-specified versus label language.
Category Scores
Accurate Statements
Terbinafine hydrochloride is an allylamine antifungal.
Section 12.1: 'Terbinafine is an allylamine antifungal'. Also Section 11/12.4 aligns with allylamine class description.
Terbinafine inhibits biosynthesis of ergosterol via inhibition of the squalene epoxidase enzyme, resulting in fungal cell death.
Section 12.4: 'inhibits biosynthesis of ergosterol... via inhibition of squalene epoxidase enzyme. This results in fungal cell death...'
Terbinafine tablets are indicated for the treatment of onychomycosis of the toenail or fingernail due to dermatophytes (tinea unguium), and nail specimens should be obtained prior to initiating treatment to confirm diagnosis.
Section 1 INDICATIONS AND USAGE.
Headache is among the most frequently reported adverse events in trials of terbinafine tablets.
Section 6.1: Table 1 includes 'Headache 12.9%' vs placebo 9.5%.
Gastrointestinal symptoms are among the most frequently reported adverse events in trials of terbinafine tablets.
Section 6.1: Table 1 lists gastrointestinal symptoms (e.g., diarrhea, dyspepsia, abdominal pain, nausea, flatulence).
Rashes/skin reactions (rash, pruritus, urticaria) are among the most frequently reported adverse events in trials of terbinafine tablets.
Section 6.1: Table 1 includes 'Rash', 'Pruritus', and 'Urticaria'.
Liver test abnormalities/liver enzyme abnormalities are among the most frequently reported adverse events in trials of terbinafine tablets.
Section 6.1: Table 1 includes 'Liver Enzyme Abnormalities* 3.3%'.
Terbinafine tablets efficacy in onychomycosis was demonstrated in 3 U.S./Canadian placebo-controlled clinical trials, including outcomes in toenail and fingernail trials.
Section 14 CLINICAL STUDIES: overview and cure/effective treatment/clinical cure results.
Unsupported Statements
Terbinafine hydrochloride is the active pharmaceutical ingredient (API) in medications used to treat fungal infections of the skin and nails.
FDA label excerpt provided is specific to 'Terbinafine tablets' and does not support general statements about API presence in 'medications used to treat fungal infections of the skin'.
Terbinafine hydrochloride belongs to the drug class of allylamines.
This is partially supported for terbinafine as an 'allylamine antifungal' (Section 12.1), but the claim is not explicitly tied to 'drug class' wording in the provided label text. Marked as unsupported/overgeneral relative to label excerpt wording.
Squalene epoxidase is crucial for the synthesis of ergosterol.
The label states ergosterol biosynthesis occurs via inhibition of squalene epoxidase enzyme, but 'crucial' is not an FDA-labeled term in the provided text.
Terbinafine hydrochloride disrupts the integrity of the fungal cell membrane by blocking ergosterol production.
Label supports ergosterol biosynthesis inhibition and that ergosterol is an essential component of the fungal cell membrane, and that the mechanism results in increased membrane permeability. However, the claim specifically attributes disruption 'by blocking ergosterol production' and does not match the label nuance that cell death is 'primarily due to' increased permeability from squalene accumulation.
Terbinafine hydrochloride leads to fungal cell death.
Mechanism text supports this, but it is not clearly expressed as a distinct pharmacodynamic statement beyond Section 12.4. This is actually supported; therefore not listed—removed from unsupported.
Terbinafine hydrochloride is primarily used to treat dermatophyte infections affecting the skin, hair, and nails.
Provided FDA label excerpt indicates terbinafine tablets are indicated for onychomycosis (nails) due to dermatophytes; it does not support skin/hair indications or 'primarily used'.
Terbinafine hydrochloride is used to treat onychomycosis (fungal infections of the nails).
Supported (but overgeneralized without specifying dermatophytes). The label indicates onychomycosis due to dermatophytes.
Terbinafine hydrochloride is used to treat tinea pedis (athlete's foot).
Not supported by the provided FDA label excerpt (indication section only addresses onychomycosis of toenail/fingernail).
Terbinafine hydrochloride is used to treat tinea cruris (jock itch).
Not supported by the provided FDA label excerpt.
Terbinafine hydrochloride is used to treat tinea corporis (ringworm).
Not supported by the provided FDA label excerpt.
Terbinafine hydrochloride is available in oral tablets for systemic treatment of more widespread or severe infections, particularly nail fungus.
The FDA label excerpt provided is only for terbinafine tablets for nail onychomycosis; it does not support 'systemic treatment', 'more widespread or severe infections', or comparative severity language.
Terbinafine hydrochloride is available as topical creams and sprays for localized skin infections.
Not supported by the provided FDA label excerpt (label sections shown do not include topical formulations/usage).
Information on specific patent expiry dates for terbinafine hydrochloride API can be found on specialized resources.
Not supported or addressed in the provided FDA label excerpt.
Generic versions of terbinafine hydrochloride become available after expiry of primary patents.
Not supported by the provided FDA label excerpt.
Potential side effects of oral terbinafine hydrochloride include skin reactions.
Label excerpt supports dermatological adverse events (rash, pruritus, urticaria), so this is broadly consistent; however 'skin reactions' is non-specific. Still supported in substance; therefore not listed.
Less commonly, liver problems have been reported with terbinafine hydrochloride.
Label excerpt provides liver enzyme abnormalities frequency in trials but does not use 'less commonly' language in the provided text.
Topical formulations of terbinafine hydrochloride are generally associated with fewer systemic side effects.
Not supported by the provided FDA label excerpt.
Topical terbinafine hydrochloride formulations typically cause localized skin irritation.
Not supported by the provided FDA label excerpt.
Alternative antifungal medications to terbinafine hydrochloride include azoles such as fluconazole.
Not supported by the provided FDA label excerpt.
Alternative antifungal medications to terbinafine hydrochloride include azoles such as itraconazole.
Not supported by the provided FDA label excerpt.
Alternative antifungal medications to terbinafine hydrochloride include echinocandins.
Not supported by the provided FDA label excerpt.
Extensive clinical trials have demonstrated efficacy of terbinafine hydrochloride in treating various fungal infections.
Label excerpt provided demonstrates efficacy for onychomycosis; it does not support 'various fungal infections'.
Studies have shown high cure rates with terbinafine hydrochloride, particularly for onychomycosis and tinea infections.
Label excerpt supports cure rates for onychomycosis but does not support tinea infections.
Oral terbinafine hydrochloride is considered a first-line treatment option due to effectiveness and relatively short treatment durations compared to some older therapies.
Not supported by the provided FDA label excerpt (no 'first-line' or comparative older therapies language).
Terbinafine hydrochloride products in various formulations have received approval from major regulatory bodies worldwide, including the U.S. Food and Drug Administration (FDA).
The provided FDA label excerpt supports FDA labeling for tablets, but the claim about 'various formulations' and worldwide approvals is not supported by the provided excerpt.
Terbinafine hydrochloride products in various formulations have received approval from major regulatory bodies worldwide, including the European Medicines Agency (EMA).
Not supported by the provided FDA label excerpt.
Regulatory approvals for terbinafine hydrochloride are based on comprehensive reviews of safety and efficacy data.
Generic regulatory statement not supported by the provided FDA label excerpt.
Contradictions
Low
AI Statement
Terbinafine hydrochloride is used to treat tinea pedis (athlete's foot).
Label Reference
Section 1 INDICATIONS AND USAGE (label provided only indicates onychomycosis of toenail/fingernail due to dermatophytes).
Important Omissions
Dose, dosage regimen, and administration instructions for terbinafine tablets (e.g., treatment duration and dosing schedule).
Importance:
Moderate
Any contraindications and warnings/precautions content.
Importance:
Moderate
Specific warnings and precautions details that may be clinically important for safe use (the response did not cover any).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported/overreaching indication claims (tinea pedis/cruris/corporis and skin/hair use) could mislead toward off-label use for infections not covered by the provided label indication. Mechanism and adverse-event statements are generally aligned, but generalizations about safety for topical formulations are unsupported.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Multiple claims extend beyond the provided FDA label indication (onychomycosis) to other tinea conditions and general skin/hair infections, and include several unsupported general/market/alternative-drug statements.
Suggested Improvement
Limit indications to terbinafine tablets for onychomycosis of toenail/fingernail due to dermatophytes, and remove or clearly qualify any statements not present in the provided FDA label excerpt (e.g., tinea pedis/cruris/corporis, topical formulations, patent/EMA/worldwide approval, first-line assertions, and non-labeled alternative therapy lists).